Chinese political body wants more progress on hospital reforms

China

The pace of hospital reforms in China needs to go faster as patient access to services continues to lag and costs are not under control--with the insurance reimbursement system a focus.

News service China.org.cn said those issues prompted a fresh wave of proposals to the Chinese People's Political Consultative Conference (CPPCC) National Committee, the country's top political advisory body.

Among the suggestions is a new system of insurance payments that would fund hospitals to pay staff better and avoid reliance on markups for prescription drugs sold on site as a primary revenue source, the online news site said citing a statement from the CPPCC.

Conference

The 13th Annual Digital Pharma East

Digital Pharma East returns to the Pennsylvania Convention Center September 17–20, bringing together over 1000 attendees from biotech and pharma, to better understand how to present business plans, justify budget and innovation, and de-risk proposals getting shut down — essentially, understand how they can return to the office and become champions for their internal digital needs. Join us and save 15% on standard rates when you register with Discount Code DPE19Fierce.

In April, the government announced subsidies to expand a program to wean public hospitals from markups on drugs sold on site to now cover 200 public hospitals from 100 currently.

But as China.cn.org points out, the many rural hospitals and clinics fall outside the pilot, making it necessary to consider how to shift insurance payments to community clinics.

China is trying to target subsidies as part of a broad effort to restructure healthcare delivery. Doctors at major public hospitals face increasing patient loads and low pay, while patients may have to endure long waiting times for a consultation.

- here's the Xinhua story from China.org.cn

Read more on

Suggested Articles

Leading Indian drugmakers Sun Pharma, Cipla, Aurobindo and Dr. Reddy's are all trying to expand their presences in China.

Hanmi loses Janssen obesity pact, while Yuhan signs NASH deal with Boehringer. GSK sells a Chinese site to Fosun as it opens facilities in Singapore.

Even as GlaxoSmithKline has opened its most advanced manufacturing site in Asia, it is selling an older plant in China to Fosun Pharma.